Education
About Us
Working with TipRanks
Follow Us
Tempest Therapeutics (TPST)
NASDAQ:TPST
TPST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.70 - $6.00
Previous CloseN/A
Volume2.28M
Average Volume (3M)651.56K
Market Cap
$35.87M
Enterprise Value$31.75M
Total Cash (Recent Filing)$73.29M
Total Debt (Recent Filing)$572.00K
Price to Earnings (P/E)―
Beta3.07
Next Earnings
May 08, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding43,642,070
10 Day Avg. Volume450,214
30 Day Avg. Volume651,563
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-83.34
Enterprise Value/Ebitda-0.94
Forecast
1Y Price Target
$21.67Price Target Upside2542.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering0
---
Tempest Therapeutics News
PremiumCompany Announcements
Tempest Therapeutics Reports Q3 2024 Financial Results
---
Bulls Say, Bears Say
Bulls Say
PartnershipRoche will supply atezolizumab for the upcoming Phase 3 study, offering significant cost savings for Tempest.
Regulatory AdvancementThe company received FDA clearance to proceed with a Phase 3 study of amezalpat in combination with current standard of care, providing a significant regulatory advancement.
Bears Say
Financial NeedsTempest will still require a sizable cash infusion to fully support Phase 3 development, which is estimated to cost approximately $100 million.
Stock PerformanceThe expected study cost versus current cash balance is a primary reason for the significant weakness in the shares following the survival update and management commentary.
---
Ownership Overview
8.16% Insiders
0.84% Mutual Funds
8.57% Other Institutional Investors
81.93% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TPST FAQ
What was Tempest Therapeutics’s price range in the past 12 months?
Tempest Therapeutics lowest stock price was $0.70 and its highest was $6.00 in the past 12 months.
What is Tempest Therapeutics’s market cap?
Tempest Therapeutics’s market cap is $35.87M.
When is Tempest Therapeutics’s upcoming earnings report date?
Tempest Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 42 days.
How were Tempest Therapeutics’s earnings last quarter?
Currently, no data Available
Is Tempest Therapeutics overvalued?
According to Wall Street analysts Tempest Therapeutics’s price is currently Undervalued.
Does Tempest Therapeutics pay dividends?
Tempest Therapeutics does not currently pay dividends.
What is Tempest Therapeutics’s EPS estimate?
Tempest Therapeutics’s EPS estimate is -0.25.
How many shares outstanding does Tempest Therapeutics have?
Tempest Therapeutics has 43,642,070 shares outstanding.
What happened to Tempest Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tempest Therapeutics?
Currently, no hedge funds are holding shares in TPST
---
Tempest Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.67 (2542.68% Upside)
$21.67 (2542.68% Upside)
Blogger Sentiment
Bullish
TPST Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.33%
12-Months-Change
Fundamentals
Return on Equity
-691.89%
Trailing 12-Months
Asset Growth
41.06%
Trailing 12-Months
Company Description
Tempest Therapeutics
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
---
TPST Stock 12 Month Forecast
Average Price Target
$21.67
▲(2542.68% Upside)
Technical Analysis
Fate Therapeutics
―
Adaptimmune Therapeutics
―
Allogene Therapeutics
―
Immatics
―
Biohaven Ltd.
―
Best Analysts Covering TPST
1 Year
1 Year Success Rate
2/10 ratings generated profit
1 Year Average Return
-14.94%
reiterated a buy rating 4 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -14.94% per trade.
---